{"doi":"10.1111/clr.14361","title":"Impact of Glycine Powder Air‐Abrasive Debridement on Peri‐Implant Mucositis: A Randomized Control Trial of Clinical, Microbial, and Immunological Changes","abstract":"AIM: Peri-implant mucositis, a dysbiosis-driven inflammatory disease, is a precursor to peri-implantitis, underscoring the need for early disease management. Therefore, we investigated the efficacy of glycine powder in resolving clinical inflammation and restoring host-microbial homeostasis. METHODS: Thirty subjects were randomized to receive either glycine powder air-abrasive debridement or ultrasonic instrumentation. Clinical parameters (probe depth [PD], modified Sulcular Bleeding Index [mSBI], modified Plaque Index [mPlI]), biofilm and peri-implant crevicular fluid were collected at baseline and at 1-day, 1-, 3-, 6-weeks and 3- and 6-months post-therapy. Microbial recolonization was examined using 16S rDNA sequencing and immune response was semi-quantified using a bead-based 17-plex microarray. RESULTS: At 6-months, both groups demonstrated non-significant reductions in mSBI when compared to baseline (p > 0.05, Wald test, mixed model for repeated measures). However, mSBI and PD decreased in the test group from week-1 to 3-months, while control group decreased at 1- and 3-weeks only. mSBI was lower in the test group when compared to controls from Week-1 to 3-months, while PD differed between groups at 6 weeks and 3-months. Glycine group demonstrated significant microbial shifts after 24-h, increases in species richness and health-compatible species, and loss of pathobionts (p < 0.001, Dunn test). Pro-inflammatory cytokines decreased from 1- to 6-weeks or 3-months (p < 0.05, Wald test). Comparable results were obtained in the ultrasonic group at 3-weeks and sustained over 6-weeks post-therapy. CONCLUSIONS: Glycine therapy leads to early and sustained change in host-microbial interactions when compared to ultrasonics, however, the changes wrought by both therapies were sustained for a maximum of 3 months. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05810558.","journal":"Clinical Oral Implants Research","year":2024,"id":447570,"datarank":0.29188652235829704,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"self_citation_contribution":0.29188652235829704,"citation_network_contribution":0.0,"self_endowment_contribution":0.29188652235829704,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":6,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9561,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT05810558"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1265651,"name":"Shweta Saraswat","orcid":"0000-0001-6847-2774","position":1,"is_corresponding":false},{"id":274566,"name":"Purnima Kumar","orcid":"0000-0001-5844-1341","position":2,"is_corresponding":false},{"id":1265650,"name":"Brian B. Partido","orcid":"0000-0002-4688-9058","position":0,"is_corresponding":true}],"reference_count":65,"raw_metadata":null,"created_at":"2026-07-19T02:02:03.354708Z","pmid":"39340233","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}